Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap53.14B
Enterprise Value76.73B
Trailing P/E73.61
Forward P/E134.01
TAK
(NYSE)Takeda Pharmaceutical Company Limited
$16.68-- (--)
Loading... - Market loading
Takeda Pharmaceutical Company (TAK) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)1.88
Forward Price/Sales1.92
Price/Book (mrq)1.11
Price/FCF (ttm)8.99
Price/OCF (ttm)7.11
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue2.72
EV/Earnings106.28
EV/EBITDA9.65
EV/EBIT31.99
EV/FCF12.99
Stock Price
Current price, 52-week range, and moving averages
Current Price$16.68
1-Day Change0.60%
52-Week High$18.90
52-Week Low$12.99
52-Week Change15.29%
YTD Change6.79%
1-Year Change16.48%
50-Day MA$17.61
200-Day MA$15.85
Avg Volume (30 day)2.97M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding3.20B
Book Value per Share$15.00
Net Cash per Share$-7.36
FCF per Share$1.84
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin62.31%
EBITDA Margin (ttm)28.19%
EBIT Margin (ttm)8.50%
Operating Margin (ttm)14.98%
Pretax Margin (ttm)4.63%
Profit Margin (ttm)2.56%
FCF Margin (ttm)20.94%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)1.50%
Return on Assets (ttm)0.75%
Return on Invested Capital (ttm)1.85%
Return on Capital Employed (ttm)2.98%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue28.21B
Gross Profit17.58B
Operating Income4.22B
Pretax Income1.31B
Net Income721.93M
EBITDA7.95B
EBIT2.40B
Diluted EPS$0.23
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow7.48B
Capital Expenditures1.57B
Free Cash Flow5.91B
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-2.50%
Dividend Growth-7.65%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)96.90B
Cash & Securities (mrq)4.12B
Net Cash (mrq)-23.59B
Net Cash per Share$-7.36
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)27.71B
Working Capital (mrq)3.18B
Total Equity (mrq)48.07B
Book Value per Share$15.00
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)1.19
Quick Ratio (mrq)0.65
Debt/Equity (mrq)0.58
Debt/EBITDA (ttm)3.48
Debt/FCF (ttm)4.69
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.62
Dividend Yield3.72%
Payout Ratio (Earnings)200.00%
Payout Ratio (FCF)33.66%
Dividend Growth (YoY)-7.65%
Years of Dividend Growth3
Ex-Dividend DateMar 31, 2027
Pay DateMar 31, 2027
Dividend FrequencySemi-Annual
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield1.36%
FCF Yield11.12%
Buyback Yield191.17%
Total Shareholder Yield194.89%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score1.65
Piotroski F-Score5/9
Dividend Score41.00
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$8.73
Graham Upside/Downside-47.69%
Frequently Asked Questions About Takeda Pharmaceutical Company Statistics
What are the key financial metrics for TAK?
Takeda Pharmaceutical Company Limited (TAK) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is TAK's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Takeda Pharmaceutical Company is overvalued or undervalued.
How do I read TAK's profitability ratios?
Takeda Pharmaceutical Company's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do TAK's debt ratios indicate?
The financial health section shows Takeda Pharmaceutical Company's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is TAK's dividend analysis?
The dividend section covers Takeda Pharmaceutical Company's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.